Form 8-K/A CYTOKINETICS INC For: Jul 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices rise 2% as US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Cytokinetics' (CYTK) Redwood-HCM Top-line Results 'Deliver on All Fronts' - Analyst
July 19, 2021 1:58 PM EDTEarlier today, Cytokinetics, Inc (NASDAQ: CYTK) announced positive topline results from Cohorts 1 and 2 of Redwood-HCM - the Phase 2 clinical trial of CK-3773274 (CK-274), an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM).
Throughout the trial, the CK-274 demonstrated high response rates, significant treatment effects and a favorable safety profile, reporting no serious adverse events attributable to CK-274 and no treatment interruptions occurring.
Reacting to the data readout, H.C. Wainwright & Co's analyst Joseph Pantginis believes the drug delivered on all fronts as expected and demonstrates... More
Cytokinetics (CYTK) PT Raised to $53 at H.C. Wainwright
July 19, 2021 12:27 PM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Cytokinetics (NASDAQ: CYTK) to $53.00 (from $41.00) while maintaining a Buy rating.
... More